Boston Scientific Corporation BSX
Super Investor & Insider
5
Fondi che lo detengono
#159
Rank consenso
7.1%
% dei portafogli
$312.4M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | 3.06% | Add 42.48% | 4,195,089 | $263.2M |
| Polen Capital Management · Polen Capital Management | 0.25% | Reduce 85.58% | 579,739 | $36.4M |
| Stephen Mandel · Lone Pine Capital | 0.05% | Reduce 48.11% | 104,655 | $6.6M |
| Dodge & Cox · Dodge & Cox | 0% | — | 88,885 | $5.6M |
| Mairs & Power · Mairs & Power | 0.01% | — | 10,176 | $638,544 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Boston Scientific Corporation develops, manufactures, and markets a broad portfolio of medical devices designed for minimally invasive procedures worldwide. The company specializes in innovative technologies that address critical health needs across cardiology, endoscopy, and neuromodulation. Its Cardiovascular segment…
SectorHealthcare
ExchangeNYSE
IndustryMedical Devices
CountryUnited States
Employees59,000
TickerBSX
Statistics
Market Cap$66.90B
Revenue (TTM)$20.07B
Net Income$2.89B
Net Margin14.4%
EPS$1.94
P/E19.63
P/S3.38
P/B2.70
EV/EBITDA14.46
ROE14.7%
Dividend Yield—
Price$45.01
Data: Twelve Data · Revenue = mcap / P/S